Elkrief, Arielle

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 685

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 526

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 437

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 351

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 316

A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota

Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 250

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 246

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 208

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 112

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 97

Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection

Campanella, G., Kumar, N., Nanda, S., Singi, S., Fluder, E., Kwan, R., Muehlstedt, S., Pfarr, N., Schüffler, P. J., Häggström, I., et al. (2025) · Nature Medicine

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 69

Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy

Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., et al. (2024) · npj Precision Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 68

Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation

Elkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 48

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., et al. (2022) · OncoImmunology

Cancer Immunotherapy and BiomarkersHelicobacter pylori-related gastroenterology studies

Cited by 34

The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers

Messaoudene, M., Ferreira, S., Saint-Lu, N., Ponce, M., Truntzer, C., Boidot, R., Le Bescop, C., Loppinet, T., Corbel, T., Féger, C., et al. (2024) · Nature Communications

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 24

Impact of the ONCOBIOME network in cancer microbiome research

Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 23

First clinical proof-of-concept that FMT can overcome resistance to ICIs

Elkrief, A., & Routy, B. (2021) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 23